Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Cancer Chemotherapy and Pharmacology|February 21, 2020
The impact of patient characteristics on enzalutamide pharmacokinetics and how this relates to treatment toxicity and efficacy in metastatic prostate cancer patientsGuillemette E Benoist, Inge M van Oort, David M Burger, et al.
British Journal of Clinical Pharmacology|February 1, 2018
A clinically relevant decrease in abiraterone exposure associated with carbamazepine use in a patient with castration-resistant metastatic prostate cancerGuillemette E Benoist, Maarten J van der Doelen, Rob Ter Heine, et al.
Cancer Chemotherapy and Pharmacology|September 14, 2019
A prospective phase I multicentre randomized cross-over pharmacokinetic study to determine the effect of food on abiraterone pharmacokineticsFloor J E Lubberman, Guillemette E Benoist, Winald Gerritsen, et al.
British Journal of Clinical Pharmacology|August 26, 2021
The effect of chemotherapy on the exposure-response relation of abiraterone in metastatic castration-resistant prostate cancerEmmy Boerrigter, Guillemette E Benoist, Joanneke K Overbeek, et al.
British Journal of Clinical Pharmacology|August 20, 2021
Concentration-QT modelling in early clinical oncology settings: Simulation evaluation of performanceGael Cantet, Alienor Berges, Rhianna O'Sullivan, et al.
Biomedical Chromatography : BMC|April 8, 2024
A rapid and sensitive LC-MS/MS method for quantifying oxycodone, noroxycodone, oxymorphone and noroxymorphone in human plasma to support pharmacokinetic drug interaction studies of oxycodoneLotte M G Hulskotte, Inge Wilbrink-Pijffers, Maurits E L Arbouw, et al.
Therapeutic Drug Monitoring|February 9, 2018
Development and Validation of a Bioanalytical Method to Quantitate Enzalutamide and its Active Metabolite N-Desmethylenzalutamide in Human Plasma: Application to Clinical Management of Patients With Metastatic Castration-Resistant Prostate CancerGuillemette E Benoist, Eric van der Meulen, Inge M van Oort, et al.
Clinical Pharmacokinetics|April 24, 2016
Pharmacokinetic Aspects of the Two Novel Oral Drugs Used for Metastatic Castration-Resistant Prostate Cancer: Abiraterone Acetate and EnzalutamideGuillemette E Benoist, Rianne J Hendriks, Peter F A Mulders, et al.
Biomedical Chromatography : BMC|April 4, 2017
Analytical challenges in quantifying abiraterone with LC-MS/MS in human plasmaGuillemette E Benoist, Eric van der Meulen, Floor J E Lubberman, et al.
Molecular Oncology|March 2, 2021
Liquid biopsy reveals KLK3 mRNA as a prognostic marker for progression free survival in patients with metastatic castration-resistant prostate cancer undergoing first-line abiraterone acetate and prednisone treatmentEmmy Boerrigter, Guillemette E Benoist, Inge M van Oort, et al.
Pageof 2